Contraceptive Tablet Manufacturing in European Union: Market Size, Businesses & Forecast 2026

The contraceptive tablet manufacturing industry in the European Union comprises the industrial formulation, pressing, and packaging of oral hormonal contraceptives, including combined and progestogen-only pills. The industry operates within a highly regulated framework supervised by the European Medicines Agency (EMA), ensuring strict therapeutic adherence and consumer safety. According to Eurostat data, broader EU exports of medicinal and pharmaceutical products grew to a record high of €221 billion in 2025 (Eurostat), indicating strong, price-driven structural tailwinds for regional pharmaceutical manufacturing facilities. The sector is moving toward advanced, low-dose synthetic hormone co

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Contraceptive Tablet Manufacturing in European Union industry cover?

This industry focuses on the mass production of oral solid-dose medications intended for temporary pregnancy prevention. The scope encompasses the manufacturing of combined oral contraceptive pills (COCs), which blend synthetic estrogens and progestogens, as well as progestogen-only pills (POPs), commonly referred to as mini-pills. Activities include the processing of active pharmaceutical ingredients (APIs), excipient blending, high-precision tablet pressing, and specialized blister packaging designed for sequential daily compliance.

• •Primary classification falls under NACE Code 21.20, which covers the manufacture of pharmaceutical preparations.
• •Production includes multi-phase compliance packs, such as 24 active and 4 placebo tablet regimens.
• •The scope is strictly limited to oral hormonal tablets, excluding long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) or transdermal patches.

Who operates in the industry and how is it structured?

The market structure is highly concentrated and dominated by major multinational pharmaceutical corporations that leverage centralized, high-throughput manufacturing plants across Western and Central Europe. These companies manage complex, globally integrated supply chains to secure active hormonal compounds, which are subsequently formulated into final dosage forms under strict European Good Manufacturing Practice (GMP) protocols. Production activities are strategically co-located within prominent European chemical clusters to optimize logistics, technology transfers, and specialized labor resources.

• •Manufacturing is heavily centered in countries with legacy pharmaceutical infrastructure, such as Germany, France, Belgium, and Ireland.
• •Operators primarily distribute through centralized European wholesale channels to public healthcare registries and commercial pharmacies.
• •Production requires dedicated, isolated cleanroom facilities to prevent cross-contamination from potent hormonal materials, establishing high entry barriers.

What drives demand in the industry?

The volume of contraceptive tablet manufacturing is fundamentally driven by national public health initiatives, institutional reimbursement frameworks, and shifting consumer demographics across the EU. European governments increasingly support reproductive health access by integrating oral contraceptives into statutory health insurance or state-subsidized programs. Furthermore, demand is sustained by consistent clinical preferences for oral medications to manage hormonal conditions like endometriosis and dysmenorrhea alongside family planning purposes.

• •National reimbursement policies, such as France's free contraception expansions for young women, directly stabilize industrial volume demands.
• •The European Medicines Agency (EMA) initiatives to map out gaps in women's health medicines in 2026 continue to shape pipeline priorities.
• •A steady medical transition toward newer, low-risk generation progestogens sustains product lifecycle reformulations.

Who are the notable companies in the industry?

The competitive dynamic features a mix of global diversified pharmaceutical giants and dedicated specialty manufacturers holding marketing authorizations throughout the EU bloc. Companies compete on formulation innovation, patent lifecycles, and cost-efficient generic manufacturing capabilities. Production often relies on centralized EU marketing authorizations, granting manufacturers the ability to distribute standard formulations seamlessly across all member states.

• •Bayer AG operates as a legacy market leader with extensive European manufacturing sites specializing in hormonal formulations.
• •Gedeon Richter Plc, based in Hungary, is a prominent European manufacturer heavily focused on original and generic women's healthcare portfolios.
• •Exeltis, a division of the global group Insud Pharma, maintains significant oral contraceptive manufacturing and marketing operations within Europe.
• •Mylan (Viatris Inc.) produces a broad suite of generic oral contraceptive tablets distributed throughout the European single market.

What are the recent trends and outlook?

Recent developments are characterized by shifting product preferences toward next-generation synthetic and bio-identical estrogens that boast improved safety profiles regarding venous thromboembolism risks. Manufacturing facilities are scaling up specialized lines to accommodate complex combination regimens featuring native molecules. The strategic outlook remains stable, reinforced by the structural health of the wider European pharmaceutical ecosystem.

• •Manufacturing lines have increasingly integrated newer compounds like estetrol monohydrate and drospirenone, utilized in products like Drovelis approved by the EMA.
• •EU external trade data from 2025 indicates a 16% annual increase in pharmaceutical exports, highlighting resilient industrial capacity across the region.
• •Manufacturers are increasingly adopting sustainable engineering solutions to minimize active hormone discharge in factory wastewater, aligned with EU environmental regulations.

How is the industry regulated?

Compliance within the industry is governed by an interconnected network of European and national regulatory bodies enforcing rigid quality and safety standards. Manufacturers must secure a Manufacturing Authorization from relevant national competent authorities and valid Marketing Authorisations from the European Medicines Agency (EMA) before commercial production. Regular inspections assess strict adherence to European Good Manufacturing Practice (GMP) standards, active substance tracking, and post-market pharmacovigilance commitments.

• •Every production batch must comply with EU GMP Part I for medicinal products and Part II for active pharmaceutical ingredients.
• •The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) regularly updates mandatory safety and labeling directives for hormonal tablets, such as desogestrel guidelines in July 2026.
• •Facility designs must incorporate strict environmental controls under EU Regulation 1907/2006 (REACH) concerning chemical and hormonal handling.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat International Trade in Medicinal and Pharmaceutical Products 2025 ·
• European Medicines Agency (EMA) Product Information and Committee Decisions 2026 ·
• European Commission NACE Rev. 2 Statistical Classification of Economic Activities